AmyloidosisRIA-HIBANCT01347047
HIBA-Institutional Registry of Amyloidosis
An observational study of Amyloidosis, run by Hospital Italiano de Buenos Aires at 1 site in Argentina.
Trial summary
1. Creating a population-based registry system Amyloidosis prospective epidemiological survey risk factors diagnosis prognosis treatment monitoring survival 2. Describe the occurrence of amyloidosis in the population of HIBA, Hospital Italiano de Buenos Aires. 3. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Amyloidosis
- How many people
- 500 participants
- Where
- 1 siteArgentina
- Study dates
- Apr 2011to Jul 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults over 18 years old with diagnosis or suspected amyloidosis of Italiano Hospital of Buenos Aires
Who may be able to join
- Patients over 18 years:
- Confirmed amyloidosis: Proof of deposit of amyloid pathology by tissue biopsy in abdominal fat, bone marrow, rectum or organ involved (eg, kidney, liver, sural nerve)
- Clinically compatible case of Amyloidosis :
Who cannot join
- Refusal to participate in the study or the informed consent process by the patient or legal representative or refusal to consent to participate in the study in the case of minors.
Trial locations and contacts
1 site in 1 country.
Argentina1 site
Hospital Italiano de Buenos Aires
Buenos Aires, Buenos Aires, C1199
About this study
Official title: Institutional Registry of Amyloidosis (Hospital Italiano de Buenos Aires)
- Creating a population-based registry system Amyloidosis prospective epidemiological survey
- risk factors
- diagnosis
- prognosis
- treatment
- monitoring
- survival
- Describe the occurrence of amyloidosis in the population of HIBA, Hospital Italiano de Buenos Aires.
- Describe the characteristics of clinical presentation, evolution and predisposing factors of amyloidosis.
Read the detailed description
Amyloidosis is a systemic disease that is usually a result of misfolded proteins in the form of amorphous fibrillar material in various tissues and can cause progressive dysfunction of the same. The prevalence of amyloidosis varies depending on the population concerned and the type of amyloid. While prevalence in the general population is unknown, according to estimates by the Mayo Clinic this prevalence is 1 in 90 666% in the U.S. In England this disease generated about 0.0084% (1367 / 16232579) of all hospital visits between April 2008 and April 2009.
The most common clinical manifestations include cardiac disease, renal and liver function, but it may vary widely depending on the type of amyloidosis, the organ infected and extent of the deposits. Amyloid infiltration can produce signs and symptoms that may be very similar to other rheumatic diseases. This may suggest potential clinical polymorphic underdiagnosis due to low clinical suspicion.
The registries are organized systems of systematic data collection of a large number of patients quickly and efficiently on a particular disease at a given time.
The main difficulty of the registries is the guarantee of the quality of their data.
The main objectives of the registry are:
- Understand risk factors and prognosis.
- Evaluate the diagnostic and therapeutic comparison with current standards.
- Advance knowledge of the disease to optimize the assessment, treatment and monitoring of patients.
- Analyze the effectiveness of new therapies.
- Studying differences between populations.
- Quickly estimate the morbidity, mortality and resource utilization associated with a disease entity.
- Examine the course of a disease
- Formulate novel hypotheses for further prospective studies. Currently, there are registries for patients with transthyretin amyloidosis (TAHOS), global registry of transplant patients with familial amyloid poly neuropathy. Also, there are indirect registries such as the kidney transplant, heart transplant, among others.
The investigators found no data on the prevalence or incidence, evolution and prognosis of amyloidosis in our country. There are no existing records of national Amyloidosis in Latin America that could describe the behavior of this disease in our environment. Because it is a chronic disease with amyloid infiltration and can produce signs and symptoms that may be very similar to other rheumatic diseases, this clinic potentially poliform, may suggest underestimation of low clinical suspicion. As there is no cure, some patients may persist symptomatic despite adequate therapy, that is why it is important the creation of a monitoring system to generate data on the evolution and prognosis. The data registries can be used to develop new treatment guidelines and recommendations, also to inform and educate physicians on the management of this disease.
The Hospital Italiano de Buenos Aires is a center of high complexity of derivation of this type of pathology and due to the fact that the hospital, that has a private health insurance system (HIBA's health plan [plan de salud, PS], gives the unique opportunity denominators for the generation of a population on their affiliates, therefore the investigators propose to make a Institutional Registry of Amyloidosis.
- Conditions
- Amyloidosis
- Keywords
- Amyloidosis, Known or Suspected, rare diseases
- Medical subject headings
- Amyloidosis, Rare Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Epidemiologic characteristics
Survival anual
Measured: From inclusion date (daignosis) until the date of death from any cause or date of last follow up(if not dead) assessed up to 10 years
Epidemiologic characteristics
Organ response
Measured: From treatment date until the date of best organ response or documented progression or date of death from any cause, whichever came first, assessed up to 10 years
From treatment to folow up, annualy
Baseline description
Measured: at baseline
Treatment patterns
Type of treatment, duration, adverse events, completition
Measured: From diagnosis, evaluated after every line of treatment or annualy up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2011 (estimated)
- Study startApr 2011
- Primary completionJul 2026
- Study completionJul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for AmyloidosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital Italiano de Buenos Aires
- Sponsor type
- University, hospital or other
- Collaborators
- Instituto Cardiovascular de Buenos Aires, Austral University, Argentina, Hospital de Alta Complejidad en Red, Hospital de Clinicas José de San Martín, HOSPITAL BRITANICO DE BUENOS AIRES, Hospital Privado de Rosario, Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno, La Fundacion Favaloro para la Investigacion y la Docencia Medica, Sanatorio Anchorena, Centro Médico Uruguayo, Uruguay, Clínica Foianini, Bolivia
- Responsible party
- Principal investigator, MARIA LOURDES POSADAS MARTINEZ, Hospital Italiano de Buenos Aires
- Investigators
- María Lourdes Posadas-Martínez, MD, Principal investigator, Hospital Italiano de Buenos Aires, ArgentinaElsa Nucifora, MD, Study chair, Hospital Italiano de Buenos Aires, ArgentinaDiego Hernan Giunta, MD, Study chair, Hospital Italiano de Buenos Aires, ArgentinaDorotea Fantl, MD, Study chair, Hospital Italiano de Buenos Aires, ArgentinaGustavo Greloni, MD, Study chair, Hospital Italiano de Buenos Aires, ArgentinaMaria Adela Aguirre, MD, Study chair, Hospital Italiano de Buenos Aires, ArgentinaCesar Antonio Belziti, MD, Study chair, Hospital Italiano de Buenos Aires, ArgentinaPatricia Sorroche, Study chair, Hospital Italiano de Buenos Aires, Argentina
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01347047
- Sponsor's protocol ID
- 1675
- Acronym
- RIA-HIBA
- Status last verified
- Jul 2026
- First submitted
- 2 May 2011
- Last updated
- 21 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Decotto S, Domenech P, Blanco R, Rossi E, Posadas-Martinez ML, Carretero M, Aguirre A, Nucifora E, Brulc E, Falconi M, Pizarro R, Perez de Arenaza D. The role of nutritional status, measured by serum albumin, as a prognostic factor in wild-type transthyretin amyloidosis. Acta Cardiol. 2026 Jun;81(4):539-545. doi: 10.1080/00015385.2026.2669696. Epub 2026 May 8.
PubMed 42102288Vaena M, Aguirre MA, Epstein T, Schalum A, Hilbert FE, Posadas-Martinez ML, Carretero M. Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort study. Sci Rep. 2025 Aug 19;15(1):30396. doi: 10.1038/s41598-025-14526-7.
PubMed 40830173Decotto S, Corna G, Villanueva E, Arenaza DP, Seropian I, Falconi M, Oberti P, Aguirre MA, Posadas-Martinez ML, Carretero M, Agatiello CR, Pizarro R. Prevalence of moderate-severe aortic stenosis in patients with cardiac amyloidosis in a referral center. Arch Cardiol Mex. 2024;94(1):71-78. doi: 10.24875/ACM.22000074.
PubMed 38507302Decotto S, Iroulart JM, Roveda G, Villanueva E, Aguirre MA, Posadas-Martinez ML, Nucifora E, Pizarro R, Perez de Arenaza D. Significant tricuspid regurgitation is associated with adverse outcomes in patients with transthyretin amyloid cardiomyopathy. Arch Peru Cardiol Cir Cardiovasc. 2024 Jun 24;5(2):e388. doi: 10.47487/apcyccv.v5i2.388. eCollection 2024 Apr-Jun.
PubMed 39015189Perez Lloveras E, Decotto S, Villanueva E, Marco MA, Carretero M, Posadas-Martinez ML, Perez De Arenaza D, Nucifora E, Aguirre MA. [Heart failure secondary to amyloidosis AL: diagnosis and treatment]. Medicina (B Aires). 2023;83(5):811-815. Spanish.
PubMed 37870341Villanueva E, Carretero M, Aguirre MA, Negro A, Belziti CA, Posadas-Martinez ML, Nucifora EM, Baratta S, Costabel JP, Higa C, Rivas C, Fernandez A, Quiroga A, Dumont CA, Volberg VI, Streitenberg GM, Perez de Arenaza D. [Specific pharmacological treatment guide for transthyretin amyloid cardiomyopathy, 2021]. Medicina (B Aires). 2022;82(2):275-288. Spanish.
PubMed 35417392Carretero M, Saez MS, Posadas-Martinez ML, Aguirre MA, Sorroche P, Negro A, Calandra CR, Salutto V, Lautre A, Conti E, Leon-Cejas L, Reisin R, Nucifora EM, Rugiero M. [Practice guideline for the treatment of familial amyloid polyneuropathy]. Medicina (B Aires). 2022;82(2):262-274. Spanish.
PubMed 35417391Saez MS, Aguirre MA, Perez de Arenaza D, Sorroche P, Nucifora E, Posadas Martinez ML. Epidemiology of variant transthyretin amyloidosis at a reference center in Argentina. Mol Genet Genomic Med. 2021 Nov;9(11):e1812. doi: 10.1002/mgg3.1812. Epub 2021 Oct 20.
PubMed 34668655Alfonsin AE, Escada SS, Kohan D, Valeo Chulvi MP, Posadas Martinez ML, Aguirre MA, Nucifora EM. [Transdisciplinarity in the approach to amyloidosis]. Rev Fac Cien Med Univ Nac Cordoba. 2021 Sep 18;78(3):313-316. doi: 10.31053/1853.0605.v78.n3.32341. Spanish.
PubMed 34617706Nucifora EM, Aguirre MA, Sorroche P, Saez MS, Fantl D, Rocca JA, Perez de Arenaza D, Varela CF, Greloni G, Garcia Rivello H, Basquiera AL, Alberbide JA, Giunta DH, Boietti BR, Posadas Martinez ML. AL amyloidosis in Argentina: hospital Italiano de Buenos Aires. Amyloid. 2019;26(sup1):99-100. doi: 10.1080/13506129.2019.1582485. No abstract available.
PubMed 31343332Aguirre MA, Boietti BR, Nucifora E, Luxardo R, Sorroche P, Saez S, Giunta DH, Posadas-Martinez ML. [AA amyloidosis. A single institution cohort study]. Medicina (B Aires). 2019;79(4):276-279. Spanish.
PubMed 31487247Aguirre MA, Nucifora EM, Rugiero M, Sorroche P, Saez MS, Giunta DH, Posadas-Martinez ML, Boietti BR. Transthyretin-related hereditary amyloidosis in an Argentinian family with TTR Tyr114Cys mutation. Amyloid. 2017 Mar;24(sup1):102. doi: 10.1080/13506129.2017.1291422. No abstract available.
PubMed 28434328Aguirre MA, Boietti BR, Nucifora E, Sorroche PB, Gonzalez Bernaldo de Quiros F, Giunta DH, Posadas-Martinez ML. Incidence rate of amyloidosis in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort. Amyloid. 2016 Sep;23(3):184-187. doi: 10.1080/13506129.2016.1207626. Epub 2016 Jul 28.
PubMed 27470486
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Institutional Registry of Amyloidosis (Hospital Italiano de Buenos Aires)
- ClinicalTrials.gov ID
- NCT01347047
- Acronym / sponsor ID
- RIA-HIBA / 1675
- Conditions
- Amyloidosis
- Keywords
- Amyloidosis, Known or Suspected, rare diseases
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Hospital Italiano de Buenos AiresUniversity, hospital or other
- Collaborators
- Instituto Cardiovascular de Buenos Aires, Austral University, Argentina, Hospital de Alta Complejidad en Red, Hospital de Clinicas José de San Martín, HOSPITAL BRITANICO DE BUENOS AIRES, Hospital Privado de Rosario, Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno, La Fundacion Favaloro para la Investigacion y la Docencia Medica, Sanatorio Anchorena, Centro Médico Uruguayo, Uruguay, Clínica Foianini, Bolivia
- Study start
- Apr 2011 (actual)
- Primary completion
- Jul 2026 (actual)
- Study completion
- Jul 2026 (actual)
- First posted
- 4 May 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Creating a population-based registry system Amyloidosis prospective epidemiological survey
- risk factors
- diagnosis
- prognosis
- treatment
- monitoring
- survival
- Describe the occurrence of amyloidosis in the population of HIBA, Hospital Italiano de Buenos Aires.
- Describe the characteristics of clinical presentation, evolution and predisposing factors of amyloidosis.
Detailed description
Amyloidosis is a systemic disease that is usually a result of misfolded proteins in the form of amorphous fibrillar material in various tissues and can cause progressive dysfunction of the same. The prevalence of amyloidosis varies depending on the population concerned and the type of amyloid. While prevalence in the general population is unknown, according to estimates by the Mayo Clinic this prevalence is 1 in 90 666% in the U.S. In England this disease generated about 0.0084% (1367 / 16232579) of all hospital visits between April 2008 and April 2009.
The most common clinical manifestations include cardiac disease, renal and liver function, but it may vary widely depending on the type of amyloidosis, the organ infected and extent of the deposits. Amyloid infiltration can produce signs and symptoms that may be very similar to other rheumatic diseases. This may suggest potential clinical polymorphic underdiagnosis due to low clinical suspicion.
The registries are organized systems of systematic data collection of a large number of patients quickly and efficiently on a particular disease at a given time.
The main difficulty of the registries is the guarantee of the quality of their data.
The main objectives of the registry are:
- Understand risk factors and prognosis.
- Evaluate the diagnostic and therapeutic comparison with current standards.
- Advance knowledge of the disease to optimize the assessment, treatment and monitoring of patients.
- Analyze the effectiveness of new therapies.
- Studying differences between populations.
- Quickly estimate the morbidity, mortality and resource utilization associated with a disease entity.
- Examine the course of a disease
- Formulate novel hypotheses for further prospective studies. Currently, there are registries for patients with transthyretin amyloidosis (TAHOS), global registry of transplant patients with familial amyloid poly neuropathy. Also, there are indirect registries such as the kidney transplant, heart transplant, among others.
The investigators found no data on the prevalence or incidence, evolution and prognosis of amyloidosis in our country. There are no existing records of national Amyloidosis in Latin America that could describe the behavior of this disease in our environment. Because it is a chronic disease with amyloid infiltration and can produce signs and symptoms that may be very similar to other rheumatic diseases, this clinic potentially poliform, may suggest underestimation of low clinical suspicion. As there is no cure, some patients may persist symptomatic despite adequate therapy, that is why it is important the creation of a monitoring system to generate data on the evolution and prognosis. The data registries can be used to develop new treatment guidelines and recommendations, also to inform and educate physicians on the management of this disease.
The Hospital Italiano de Buenos Aires is a center of high complexity of derivation of this type of pathology and due to the fact that the hospital, that has a private health insurance system (HIBA's health plan [plan de salud, PS], gives the unique opportunity denominators for the generation of a population on their affiliates, therefore the investigators propose to make a Institutional Registry of Amyloidosis.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults over 18 years old with diagnosis or suspected amyloidosis of Italiano Hospital of Buenos Aires
Key inclusion criteria (3 listed)
- Patients over 18 years:
- Confirmed amyloidosis: Proof of deposit of amyloid pathology by tissue biopsy in abdominal fat, bone marrow, rectum or organ involved (eg, kidney, liver, sural nerve)
- Clinically compatible case of Amyloidosis :
Key exclusion criteria (1 listed)
- Refusal to participate in the study or the informed consent process by the patient or legal representative or refusal to consent to participate in the study in the case of minors.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Epidemiologic characteristics
Time frame: From inclusion date (daignosis) until the date of death from any cause or date of last follow up(if not dead) assessed up to 10 years
Survival anual
Epidemiologic characteristics
Time frame: From treatment date until the date of best organ response or documented progression or date of death from any cause, whichever came first, assessed up to 10 years
Organ response
From treatment to folow up, annualy
Time frame: at baseline
Baseline description
Treatment patterns
Time frame: From diagnosis, evaluated after every line of treatment or annualy up to 10 years
Type of treatment, duration, adverse events, completition
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
- Results publication: PubMed 42102288Decotto S, Domenech P, Blanco R, Rossi E, Posadas-Martinez ML, Carretero M, Aguirre A, Nucifora E, Brulc E, Falconi M, Pizarro R, Perez de Arenaza D. The role of nutritional status, measured by serum albumin, as a prognostic factor in wild-type transthyretin amyloidosis. Acta Cardiol. 2026 Jun;81(4):539-545. doi: 10.1080/00015385.2026.2669696. Epub 2026 May 8.
- Results publication: PubMed 40830173Vaena M, Aguirre MA, Epstein T, Schalum A, Hilbert FE, Posadas-Martinez ML, Carretero M. Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort study. Sci Rep. 2025 Aug 19;15(1):30396. doi: 10.1038/s41598-025-14526-7.
- Results publication: PubMed 38507302Decotto S, Corna G, Villanueva E, Arenaza DP, Seropian I, Falconi M, Oberti P, Aguirre MA, Posadas-Martinez ML, Carretero M, Agatiello CR, Pizarro R. Prevalence of moderate-severe aortic stenosis in patients with cardiac amyloidosis in a referral center. Arch Cardiol Mex. 2024;94(1):71-78. doi: 10.24875/ACM.22000074.
- Results publication: PubMed 39015189Decotto S, Iroulart JM, Roveda G, Villanueva E, Aguirre MA, Posadas-Martinez ML, Nucifora E, Pizarro R, Perez de Arenaza D. Significant tricuspid regurgitation is associated with adverse outcomes in patients with transthyretin amyloid cardiomyopathy. Arch Peru Cardiol Cir Cardiovasc. 2024 Jun 24;5(2):e388. doi: 10.47487/apcyccv.v5i2.388. eCollection 2024 Apr-Jun.
- Results publication: PubMed 37870341Perez Lloveras E, Decotto S, Villanueva E, Marco MA, Carretero M, Posadas-Martinez ML, Perez De Arenaza D, Nucifora E, Aguirre MA. [Heart failure secondary to amyloidosis AL: diagnosis and treatment]. Medicina (B Aires). 2023;83(5):811-815. Spanish.
- Results publication: PubMed 35417392Villanueva E, Carretero M, Aguirre MA, Negro A, Belziti CA, Posadas-Martinez ML, Nucifora EM, Baratta S, Costabel JP, Higa C, Rivas C, Fernandez A, Quiroga A, Dumont CA, Volberg VI, Streitenberg GM, Perez de Arenaza D. [Specific pharmacological treatment guide for transthyretin amyloid cardiomyopathy, 2021]. Medicina (B Aires). 2022;82(2):275-288. Spanish.
- Results publication: PubMed 35417391Carretero M, Saez MS, Posadas-Martinez ML, Aguirre MA, Sorroche P, Negro A, Calandra CR, Salutto V, Lautre A, Conti E, Leon-Cejas L, Reisin R, Nucifora EM, Rugiero M. [Practice guideline for the treatment of familial amyloid polyneuropathy]. Medicina (B Aires). 2022;82(2):262-274. Spanish.
- Results publication: PubMed 34668655Saez MS, Aguirre MA, Perez de Arenaza D, Sorroche P, Nucifora E, Posadas Martinez ML. Epidemiology of variant transthyretin amyloidosis at a reference center in Argentina. Mol Genet Genomic Med. 2021 Nov;9(11):e1812. doi: 10.1002/mgg3.1812. Epub 2021 Oct 20.
- Results publication: PubMed 34617706Alfonsin AE, Escada SS, Kohan D, Valeo Chulvi MP, Posadas Martinez ML, Aguirre MA, Nucifora EM. [Transdisciplinarity in the approach to amyloidosis]. Rev Fac Cien Med Univ Nac Cordoba. 2021 Sep 18;78(3):313-316. doi: 10.31053/1853.0605.v78.n3.32341. Spanish.
- Results publication: PubMed 31343332Nucifora EM, Aguirre MA, Sorroche P, Saez MS, Fantl D, Rocca JA, Perez de Arenaza D, Varela CF, Greloni G, Garcia Rivello H, Basquiera AL, Alberbide JA, Giunta DH, Boietti BR, Posadas Martinez ML. AL amyloidosis in Argentina: hospital Italiano de Buenos Aires. Amyloid. 2019;26(sup1):99-100. doi: 10.1080/13506129.2019.1582485. No abstract available.
- Results publication: PubMed 31487247Aguirre MA, Boietti BR, Nucifora E, Luxardo R, Sorroche P, Saez S, Giunta DH, Posadas-Martinez ML. [AA amyloidosis. A single institution cohort study]. Medicina (B Aires). 2019;79(4):276-279. Spanish.
- Results publication: PubMed 28434328Aguirre MA, Nucifora EM, Rugiero M, Sorroche P, Saez MS, Giunta DH, Posadas-Martinez ML, Boietti BR. Transthyretin-related hereditary amyloidosis in an Argentinian family with TTR Tyr114Cys mutation. Amyloid. 2017 Mar;24(sup1):102. doi: 10.1080/13506129.2017.1291422. No abstract available.
- Individual participant dataSharing planned: No
Related trials for Amyloidosis
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
Active, not recruitingPhase 2
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
Alzheimer's Disease
Active, not recruitingObservational study
A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany
ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Active, not recruitingPhase 3
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
Transthyretin Amyloid Cardiomyopathy
RecruitingObservational study
PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)
Aging
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
María Lourdes Posadas-Martínez, MD principal investigator
Hospital Italiano de Buenos Aires, Argentina
Elsa Nucifora, MD study chair
Hospital Italiano de Buenos Aires, Argentina
Diego Hernan Giunta, MD study chair
Hospital Italiano de Buenos Aires, Argentina
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Amyloidosis, run by Hospital Italiano de Buenos Aires at 1 site in Argentina.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Argentina. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Epidemiologic characteristics (time frame: From inclusion date (daignosis) until the date of death from any cause or date of last follow up(if not dead) assessed up to 10 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01347047, which also lists 13 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.